ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Business deals

Eisai teams with Merck to boost sales of cancer drug

Japanese drugmaker bets future on using payments to devise dementia treatments

Eisai sees the development of treatments for Alzheimer's disease as the company's future earnings source.   © Reuters

TOKYO -- Eisai said Thursday it has agreed to collaborate with U.S. counterpart Merck on development and marketing of the Japanese pharmaceutical company's cancer drug Lenvima, a deal that also brings a timely infusion of cash.

The Japanese drugmaker thinks it can use Merck's global marketing muscle to develop Lenvima into a billion-dollar blockbuster. "We expect to attain triple the sales we could manage alone," CEO Haruo Naito said at a news conference here covering the announcement.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more